RxDoctor Payments Data

Matthew Connor, MD

Otolaryngology · Naples, FLNPI 1831412295

Payments from drug & device makers

$5,263in general payments, 2019–2025

Across 116 payments — averaging $45.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Sanofi$619
  • Regeneron Healthcare Solutions, Inc.$575
  • Aerin Medical Inc.$414
  • Inspire Medical Systems, Inc.$349
  • Optinose US, Inc.$215
  • plus $531 from 10 others

What the payments were for

  • Consulting fees$55010%
  • Travel & lodging$1202%
  • Food & beverage$4,43784%
  • Education$1553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,263 in reported general payments places this provider in the 80th percentile of 586 otolaryngology providers in Florida.

See all otolaryngology providers in Florida

Medicare billing

Part B allowed, 2024
$998,058
Medicare patients
1,322
Services billed
11,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl340$10,843
Ipratropium Bromide442$10,385
OdactraMite,d.Farinae-D.Pteronyssinus13$4,440
Famotidine317$3,305
Levocetirizine Dihydrochloride244$3,282
Fluticasone Propionate287$3,060
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth26$2,840
Epinephrine19$2,793
Ofloxacin71$2,335
Omeprazole225$2,304
Doxycycline Hyclate190$2,015
Fluocinolone Acetonide Oil53$1,816
Mupirocin218$1,239
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav107$1,010
Methylprednisolone165$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alk-abello, IncOdactra$109$4,44013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 otolaryngology providers in Florida.

Other otolaryngology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →